Lixisenatide: Revolutionary Polypeptide for Effective Type 2 Diabetes Management
ProcurenetShort description
Lixisenatide, a recombinantly synthesized DNA polypeptide, mirrors the functionality of glucagon-like peptide-1 (GLP-1). It is an effective agent in managing Type 2 Diabetes as it:
- Regulates blood glucose levels,
- Enhances insulin secretion,
- Inhibits glucagon secretion,
- Delays gastric emptying, amplifying digestion efficiency.
As a Research-Grade material, Lixisenatide serves as a critical tool in scientific exploration. In conjunction with a balanced diet and regular physical activity, it favors glycemic control, elevating the life quality for Type 2 Diabetes patients. Available in various quantities to best fit specific research needs.
-
Procurenet Team Tshim Sha Tsui
Hong Kong
3 years
Description
Lixisenatide, scientifically termed as N6-(dimethylglycyl)-L-lysyl-L-glutamyl-L-tyrosyl-glycyl-L-threonyl-L-methionyl-L-α-glutamyl-L-glycine, is a game-changing pharmaceutical compound designed to bring about effective management of type 2 diabetes. Its potency is sourced from its synthetic mimicry of human glucagon-like peptide-1(GLP-1), a pivotal therapeutic target in type 2 diabetes treatment.
- Compound Name: Lixisenatide
- Synonyms: Lyxumia, Adlixin
- IUPAC Name: N6-(Dimethylglycyl)-L-lysyl-L-glutamyl-L-tyrosyl-glycyl-L-threonyl-L-methionyl-L-α-glutamyl-L-glycine
- CAS Number: 320367-13-3
- Molecular Formula: C215H347N61O65S
- Molecular Weight: 4857.57 g/mol
- Pharmacological Class: Incretin mimetics/GLP-1 receptor agonists
- Treatment: Providentially for type 2 diabetes when lifestyle modifications fail to deliver.
- Dosage: Customizable to the medical requirements of individuals, with the initiation at a minimal dosage, followed by increments under the careful supervision of a medical professional.
- Side Effects: Hypoglycemia, nausea, vomiting, diarrhea, and headaches may be observed.
Lixisenatide operates by imitating the role of endogenous incretin hormones, thereby promoting the release of insulin in response to glucose, delaying the pace of gastric emptying, and holding back the post-prandial elevation in the secretion of glucagon. As a result, these actions lead to a decrease in fasting and post-meal glucose concentrations.
Available in comprehensive packaging sizes ranging from 1g to 100g, Lixisenatide emerges as a suitable product for scientific research and development procedures, irrespective of their scale. This revolutionary pharmaceutical compound reflects an invaluable advancement in the realm of type 2 diabetes treatment, substantiating its place in a diverse array of medical and scientific endeavours.
